Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $19.00.

ABEO has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Finally, Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $4.54 on Friday. The firm has a market cap of $259.01 million, a price-to-earnings ratio of 4.41 and a beta of 1.13. The company’s fifty day moving average is $5.09 and its 200-day moving average is $5.22. The company has a quick ratio of 9.53, a current ratio of 6.93 and a debt-to-equity ratio of 0.05. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.65 million. Equities analysts expect that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Activity at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 69,832 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total transaction of $372,204.56. Following the completion of the sale, the chief executive officer directly owned 1,460,408 shares of the company’s stock, valued at approximately $7,783,974.64. This represents a 4.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric Crombez sold 16,284 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $82,885.56. Following the completion of the transaction, the director owned 63,456 shares in the company, valued at $322,991.04. The trade was a 20.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 209,605 shares of company stock valued at $1,101,300. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $25,000. Legal & General Group Plc bought a new position in shares of Abeona Therapeutics in the second quarter worth about $27,000. Russell Investments Group Ltd. acquired a new position in shares of Abeona Therapeutics during the 3rd quarter worth about $37,000. Truvestments Capital LLC lifted its position in shares of Abeona Therapeutics by 191.4% during the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 6,770 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in Abeona Therapeutics during the 3rd quarter valued at approximately $57,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.